Clinical characteristics of total study cohort and of the proband subset
. | Entire cohort . | Probands* . | ||||
---|---|---|---|---|---|---|
Total . | INH(−)† . | INH(+) . | Total . | INH(−) . | INH(+) . | |
Total subjects | 372 | 259 | 113 | 330 | 230 | 100 |
African American | 174 | 113 | 61 | 145 | 94 | 51 |
White | 198 | 146 | 52 | 185 | 136 | 49 |
Severe HA | 365 (98%) | 323 (98%) | ||||
Haplotype | ||||||
H1 | 213 | 153 | 60 | 191 | 137 | 54 |
H2 | 117 | 78 | 39 | 104 | 71 | 33 |
H3 | 28 | 20 | 8 | 22 | 15 | 7 |
H4 | 1 | 0 | 1 | 1 | 0 | 1 |
H5 | 3 | 1 | 2 | 2 | 0 | 2 |
Intron-22 inversion | 151 | 100 | 51 | 138 | 93 | 45 |
Intron-1 inversion | 12 | 7 | 5 | 10 | 6 | 4 |
Missense mutation | 53 | 43 | 10 | 47 | 39 | 8 |
Mutation unknown | 106 | 73 | 33 | 89 | 58 | 31 |
Age at enrollment, y | ||||||
2-3, African American | 8 | 6 | 2 | 7 | 5 | 2 |
2-3, White | 7 | 3 | 4 | 6 | 2 | 4 |
4-17, African American | 67 | 48 | 19 | 57 | 40 | 17 |
4-17, White | 72 | 49 | 23 | 65 | 43 | 22 |
18+, African American | 99 | 59 | 40 | 81 | 49 | 32 |
18+, White | 119 | 94 | 25 | 114 | 91 | 23 |
High-responder inhibitors, ≥5 BU/mL | ||||||
African American | 41/174 (24%) | 35/145 (24%) | ||||
White | 33/198 (17%) | 31/185 (17%) |
. | Entire cohort . | Probands* . | ||||
---|---|---|---|---|---|---|
Total . | INH(−)† . | INH(+) . | Total . | INH(−) . | INH(+) . | |
Total subjects | 372 | 259 | 113 | 330 | 230 | 100 |
African American | 174 | 113 | 61 | 145 | 94 | 51 |
White | 198 | 146 | 52 | 185 | 136 | 49 |
Severe HA | 365 (98%) | 323 (98%) | ||||
Haplotype | ||||||
H1 | 213 | 153 | 60 | 191 | 137 | 54 |
H2 | 117 | 78 | 39 | 104 | 71 | 33 |
H3 | 28 | 20 | 8 | 22 | 15 | 7 |
H4 | 1 | 0 | 1 | 1 | 0 | 1 |
H5 | 3 | 1 | 2 | 2 | 0 | 2 |
Intron-22 inversion | 151 | 100 | 51 | 138 | 93 | 45 |
Intron-1 inversion | 12 | 7 | 5 | 10 | 6 | 4 |
Missense mutation | 53 | 43 | 10 | 47 | 39 | 8 |
Mutation unknown | 106 | 73 | 33 | 89 | 58 | 31 |
Age at enrollment, y | ||||||
2-3, African American | 8 | 6 | 2 | 7 | 5 | 2 |
2-3, White | 7 | 3 | 4 | 6 | 2 | 4 |
4-17, African American | 67 | 48 | 19 | 57 | 40 | 17 |
4-17, White | 72 | 49 | 23 | 65 | 43 | 22 |
18+, African American | 99 | 59 | 40 | 81 | 49 | 32 |
18+, White | 119 | 94 | 25 | 114 | 91 | 23 |
High-responder inhibitors, ≥5 BU/mL | ||||||
African American | 41/174 (24%) | 35/145 (24%) | ||||
White | 33/198 (17%) | 31/185 (17%) |